Therapeutic drug monitoring of protein kinase inhibitors is a widely practiced worldwide. Based on the example of ripretinib dosage requested by a clinician, we detailed the process of method development, using a literature-based approach while ensuring the sustainability of the method to be as environmentally friendly as possible. Therefore, an UPLC-MS/MS method for ripretinib and its active metabolite was optimized and validated using the corresponding stable isotopic internal standards in human plasma. The procedure has employed mobile phase mixture of water with 1% acetic acid and 0.1% formic acid, and acetonitrile. Positive electrospray ionization was performed coupling with multiple reaction monitoring of m/z 510.4→417.4 and 510.4→389.4 for ripretinib, and 496.3→403.3 and 496.3→375.3 for N-desmethyl-ripretinib. The method was successfully validated according the current version of ICH Guideline provided by the EMA. The greenness assessment score of this procedure was evaluated and compared with previously published approaches using the AGREE metric. The validated UPLC-MS/MS method successfully monitored ripretinib and its metabolite concentrations in clinical and pre-clinical models.
Competing Interest StatementThe authors have declared no competing interest.
Funding StatementThis study was supported by Bordeaux University Hospital, Bordeaux Institute of Oncology (BRIC) and Association pour la Recherche sur les Tumeurs Cerebrales (N 283008). AS and AB were supported by a fellowship from the Fondation de France.
Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board of Institut Bergonie (Clinical Research College) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data AvailabilityAll data produced in the present study are available upon reasonable request to the authors
Comments (0)